170 related articles for article (PubMed ID: 21944982)
21. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
22. Complete remission of Waldenström's associated generalized crystal-storing histiocytosis of IgM lambda subtype with bortezomib-based combination chemotherapy.
Baird SM; Kenealy MK; Hoy R
Leuk Lymphoma; 2015; 56(11):3233-5. PubMed ID: 25837422
[No Abstract] [Full Text] [Related]
23. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
24. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
Mori A; Tamaru J; Kondo H
Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
[TBL] [Abstract][Full Text] [Related]
25. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Zinzani PL; Tani M; Alinari L; Stefoni V; Baccarani M
Leuk Res; 2003 May; 27(5):465-6. PubMed ID: 12620298
[No Abstract] [Full Text] [Related]
26. [Waldenström's hyperglobulinemic purpura, Waldenström's macroglobulinemia].
Fischer M
Thromb Diath Haemorrh Suppl; 1968; 30():155-6. PubMed ID: 5005718
[No Abstract] [Full Text] [Related]
27. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
28. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
[TBL] [Abstract][Full Text] [Related]
29. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
30. [Waldenström's macroglobulinemia--the experts opinion about new therapeutic possibilities and response criteria].
Jurczyszyn A; Skotnicki AB
Pol Arch Med Wewn; 2004 Sep; 112(3):1113-21. PubMed ID: 15727094
[No Abstract] [Full Text] [Related]
31. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
[No Abstract] [Full Text] [Related]
32. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
[TBL] [Abstract][Full Text] [Related]
34. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
35. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Bladé J; Montoto S; Rosiñol L; Montserrat E
Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
[TBL] [Abstract][Full Text] [Related]
36. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
37. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
Le Garff-Tavernier M; Herbi L; de Romeuf C; Azar N; Roos-Weil D; Bonnemye P; Urbain R; Leblond V; Merle-Beral H; Vieillard V
Haematologica; 2015 Apr; 100(4):e147-51. PubMed ID: 25552707
[No Abstract] [Full Text] [Related]
38. Nodular amyloidosis of all four eyelids: first presenting symptom of Waldenström macroglobulinaemia.
Jacoby S; Toft PB; Prause JU; Philip P; Heegaard S
Acta Ophthalmol; 2014 Jun; 92(4):392-3. PubMed ID: 23601930
[No Abstract] [Full Text] [Related]
39. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
[No Abstract] [Full Text] [Related]
40. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A; Zervas C; Kyrtsonis MC; Zomas A; Bourantas C; Anagnostopoulos N; Pangalis G
Clin Lymphoma; 2005 Mar; 5(4):270-2. PubMed ID: 15794863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
